Top Markets
Coin of the day
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Pozycja w akcjach #5110
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Cena akcji
$58.70
Ostatnia synchronizacja: 2024-01-23
Kapitalizacja rynkowa
$2.98B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Mirati Therapeutics, Inc. (MRTX)

Kategoria

Historia ceny akcji dla Mirati Therapeutics, Inc. (MRTX)
Najwyższa cena zamknięcia: $58.94 dnia 2024-01-01

Najniższa cena zamknięcia: $8.67 dnia 2013-07-01
Historia cen akcji firmy Mirati Therapeutics, Inc. od 2013 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2024 2.02%
2023 12.06%
2022 -63.56%
2021 -39.15%
2020 103.16%
2019 189.49%
2018 132.29%
2017 218.41%
2016 -84.08%
2015 98.82%
2014 1.02%
2013 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.41 -12.81%
AU
$764.47 7.08%
CH